

**Suppl. Table 3.** Characteristics of studies on the measurement properties of patient-reported outcome measures

STUDY	MEASUREMENT PROPERTIES ASSESSED	STUDY TYPE AND POPULATION SETTING	COUNTRY (LANGUAGE)	SAMPLE SIZE (% FEMALES)	MEAN OR MEDIAN AGE (RANGE), YEARS	AGE OF PSORIASIS ONSET, YEARS	DISEASE DURATION $\pm$ SD (RANGE)	PSORIASIS TYPE, N (%)	TREATMENT HISTORY OR STUDY INTERVENTION	PSORIATIC ARTHRITIS, N (%)	PSORIASIS FAMILY HISTORY, N (%)
PSORIASIS-SPECIFIC MEASURES											
Oostveen et al. [17]	Internal consistency, structural validity, and hypothesis testing of CSP	Longitudinal, observational, single-center study  Pediatric patients with scalp psoriasis, ages 6–17, with >5% scalp area involvement. Recruited from the Child-CAPTURE cohort from March 2011 to May 2012. Data analyzed from baseline visit	The Netherlands (Dutch)	94 (59.6)	Mean $\pm$ SD 12.4 $\pm$ 3.3 (6–17)	Mean $\pm$ SD 8.3 $\pm$ 4.2 (0–17)	Mean $\pm$ SD 3.7 $\pm$ 3.5 years (0–13)	Scalp psoriasis, 94 (100)	Not reported	Not reported	Not reported
	Responsiveness of CSP	Longitudinal, observational, single-center study  Pediatric patients with scalp psoriasis, ages 6–17, recruited from the Child-CAPTURE cohort from March 2011 to May 2012  Data from children with scalp psoriasis undergoing treatment were collected 1–7 months (mean $\pm$ SD 4.3 $\pm$ 1.8) following baseline assessments	The Netherlands (Dutch)	53 (not reported)	Not reported	Not reported	Not reported	Scalp psoriasis, 94 (100)	Patients treated for scalp psoriasis according to physician's opinion. Details not reported	Not reported	Not reported

Van Geel et al. [18]	Hypothesis testing and criterion validity of SPI	Cross-sectional, observational, single-center study  Pediatric patients with plaque psoriasis, ages 4–17, from the Child-CAPTURE cohort. Data extracted from visits between September 2013 and April 2014	The Netherlands (Dutch)	113 (54.9)	Median 12 (4–17)	Not reported	Not reported	Plaque psoriasis, 113 (100)	Past treatments, <i>n</i> (%): Topical, 113 (100) Dithranol, 46 (40.7) Phototherapy, 36 (31.9) Methotrexate, 15 (13.3) Cyclosporine, 1 (0.9) Fumaric acid esters, 5 (4.4) Acitretin, 1 (0.9) Dapsone, 1 (0.9) Biologicals, 7 (6.2)	Psoriasis diagnosis 3 (2.7)	69 (61.1)
----------------------	--	---	-------------------------	------------	---------------------	--------------	--------------	-----------------------------	---	--------------------------------	-----------

#### DERMATOLOGY-SPECIFIC MEASURES

Oostveen et al. [21]	Hypothesis testing of CDLQI-Dutch version	Longitudinal, observational, single-center study  Pediatric patients with psoriasis, ages 3–17, recruited from the Child-CAPTURE cohort between September 2008 and October 2011. Data analyzed from baseline visit	The Netherlands (Dutch)	125 (63.2)	Mean ± SD 10.7 ± 3.9 (3–17)	Mean ± SD 7.4 ± 3.9 (0–16)	Mean ± SD 39.2 ± 37.0 months (1–154)	Not reported	Not reported	Psoriasis diagnosis 1 (0.8)	88 (70.4)
----------------------	---	--	-------------------------	------------	-----------------------------------	-------------------------------	--	--------------	--------------	--------------------------------	-----------



Van Geel et al. [23]	Hypothesis testing of CDLQI Dutch version	Cross-sectional, observational, single-center study  Pediatric patients with psoriasis, ages 16–17, from the Child-CAPTURE cohort. Data extracted from visits between August 2011 and September 2015	The Netherlands (Dutch)	56 (57)	Mean 16.6 (16–17)	Not reported	Not reported	Not reported	Past treatments, <i>n</i> (%): Topical, 38 (68) Systemic with topical, 7 (13) Systemic without topical, 4 (7) None, 7 (13)	Not reported	Not reported
Ganemo et al. [24]	Hypothesis testing of CDLQI Swedish version	Cross-sectional observational, multicenter study  Pediatric patients with psoriasis, ages 5–16, recruited from 2 university hospitals	Sweden (Swedish)	45 (62)	Median 12 (4–16)	Median 7 (0.5–15)	Median 27 months (1–180)	Plaque psoriasis (87%)  Inverse psoriasis (36%)  Guttate psoriasis (18%)	Current psoriasis and joint pain treatment, <i>n</i> = 42 (93%): Moisturizers, 73% Topical glucocorticoid, 53% Topical calcipotriol, 56% Phototherapy, 24% Methotrexate, 2% Systemic retinoids, 2% Paracetamol or diclofenac, 4%	Joint pain, 4  Psoriasis diagnosis, 2	22 (49)

Langley et al. [25]	Responsiveness of CDLQI English version and CDLQI cartoon version	Randomized, multi-center, clinical trial  Pediatric patients with moderate-to-severe plaque psoriasis, ages 4–17 years, participating in a 12-week randomized, double-blind, placebo-controlled phase III study of etanercept with a 24-week OLE.  Questionnaires administered at baseline and weeks 2, 4, and 12. CDLQI cartoon version administered to patients 4–12 years old. CDLQI English version administered to patients 13–17 years old	USA (English)	211 (48.8)	Etanercept treatment group median 14 (4–17)  Placebo treatment group median 13 (4–17)	Not reported	Etanercept treatment group median 7 years (<1–17)  Placebo treatment group median 6 years (<1–17)	Plaque psoriasis, 211 (100)	Intervention: 12-week etanercept, <i>n</i> = 106  12-week placebo, <i>n</i> = 105	Etanercept treatment group, 5 (5)  Placebo treatment group, 14 (13)	Not reported
---------------------	---	--	---------------	------------	---	--------------	---	-----------------------------	---	---	--------------

GENERIC NONDERMATOLOGICAL MEASURES

Langley et al. [25]	Responsiveness of PedsQL	Randomized, multicenter, clinical trial  Pediatric patients with moderate-to-severe plaque psoriasis, ages 4–17, participating in a 12-week randomized, double-blind, placebo-controlled phase III study of etanercept with a 24-week OLE  Questionnaires administered at baseline and week 12	USA (English)	211 (48.8)	Etanercept treatment group median 14 (4–17)  Placebo treatment group median 13 (4–17)	Not reported	Etanercept treatment group median 7 years (<1–17)  Placebo treatment group median 6 years (<1–17)	Plaque psoriasis, 211 (100)	Intervention: 12-week etanercept, <i>n</i> = 106  12-week placebo, <i>n</i> = 105	Etanercept treatment group, 5 (5)  Placebo treatment group, 14 (13)	Not reported
---------------------	--------------------------	--	---------------	------------	---	--------------	---	-----------------------------	---	---	--------------

CSP, Children's Scalpdx in Psoriasis; SPI, Simplified Psoriasis Index; CDLQI, Children's Dermatology Life Quality Index; IQR, interquartile range; OLE, open label extension; PedsQL, Pediatric Quality of Life Inventory.

<sup>3</sup>De Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM: Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. *J Am Acad Dermatol*. 2010;62:1013–1030.